Barclays Maintains Overweight on Relay Therapeutics, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Overweight rating on Relay Therapeutics (NASDAQ:RLAY) but lowers the price target from $15 to $14.
July 26, 2024 | 11:35 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays analyst Peter Lawson maintains an Overweight rating on Relay Therapeutics but lowers the price target from $15 to $14.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100